82 results about "Therapeutic evaluation" patented technology

The invention relates to a breast cancer detecting marker by utilizing 16 specific tiny ribonucleic acids steadily existing in blood serum and blood plasma of a human body as well as a detecting method, a kit and a biological chip thereof, and the detecting marker can be used in the aspects of diagnosis and differential diagnosis of breast cancer, occurrence and recurrence forecast as well as efficacy assessment of disease complications, screening and therapeutic evaluation of medicinal active ingredients and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, the materials are conveniently taken, the samples are easy to store and the like. The method can be widely used in related work such as breast cancer census, the defects of low specificity and low sensitivity caused by insuperable individual difference of a single marker can be improved and the clinical detectable rate of the breast cancer is notably improved, and is an effective mean of early breast cancer diagnosis.

The invention discloses a wearable intelligent monitoring system for cardiovascular and cerebrovascular diseases and a method. The system comprises a signal detection module, a signal transmission module, a cloud intelligent expert system and a client which are successively connected, wherein the signal detection module is used for collecting and processing pulse wave, blood pressure wave, electrocardiogram, phonocardiogram and ballistocardiogram; the signal transmission module is used for wirelessly transmitting a monitoring signal, which is collected and processed by the signal detection module, to the cloud intelligent expert system; the cloud intelligent expert system is a cloud server system based on a CNN depth network and is used for quantitative forecast of the cardiovascular and cerebrovascular diseases; the client is used for displaying the forecast results of the cardiovascular and cerebrovascular diseases. By continuous data collection and big data integration application,the system can be used for giving the loop parameter of the local area of a body and the quantitative evaluation of the cardiovascular and cerebrovascular diseases, and has important significance in early warning, therapeutic evaluation, prevention and cure drug selection and the like for a patient suffering from the cardiovascular and cerebrovascular diseases.

The invention belongs to the technical field of immunodiagnosis, and discloses a thyroxine (T4) enzymatic chemiluminescence quantitative determination kit. The kit disclosed by the invention consists of a T4 standard product, an antibody pre-coated reaction plate, a horseradish peroxidase marker, diluent, cleaning mixture, and chemiluminescence substrate liquid. The kit disclosed by the invention has the advantages of quickness, handiness, sensitiveness, cheapness and high repeatability, and is an important index for diagnosis and therapeutic evaluation of hyperthyroidism and hypothyroidism. The invention has high clinic use value. The invention also provides a method to prepare the kit.

The invention relates to a set of biomarkers for diagnosing AD in a subject or determining a risk of the AD in the subject. Diagnostic markers are a cholic acid, a chenodeoxycholic acid, an allocholicacid, a benzpyrole-3-lactic acid and tryptophan. The invention also provides the application of the above diagnostic markers in preparation of a differential diagnostic reagent for an Alzheimer's disease and a kit. Plasma fingerprint spectrum analysis of AD patients, MCI patients, Ctrl and NDC populations is performed through a plasma sample collection-plasma sample pretreatment-ultra-high performance liquid chromatography and mass spectrometry analysis method, and contents of the above five diagnostic markers are detected so that the markers are applied to preparation of products related todiagnosis of the Alzheimer's disease, and therapeutic evaluation. The markers can evaluate an early phase of the Alzheimer's disease, accuracy is high, a detection speed is fast, cost is low, traumasare small, and patients can easily accept. A scientific and effective treatment plan is provided for the Alzheimer's disease and a good application prospect is possessed.

The invention relates to a detection system for detecting a human immune state and belongs to the technical field of gene detection. The detection system provided by the invention is used for detecting 20 genes, including IFI27, ISG15, IFI44L, RSAD2, HERC5, IFITM3, IFI44, IFIT3, EPSTI1, IFIT1, HP, ANXA3, ARG1, FCGR1B, S100A12, MMP9, IL18R1, TLR3, GYG1 AND FCGR1A in peripheral blood; the assessment for the human immune state can be realized in the manner of increasing or reducing the expression level of each gene; and the genes are utilized to guide accurate medical treatment, including disease accurate parting, prognosis, treatment tracking and therapeutic evaluation. The detection system has excellent clinic application values and wide application prospects.

The invention discloses a [<18>F] AlF marked positron emission tomography (PET) polypeptide probe and a preparation method thereof. The probe comprises TMTP1 polypeptide and NOTA, which are connected together, and the structural formulae of the TMTP1 polypeptide and the NOTA are shown in the description. According to the [<18>F] AlF marked positron emission tomography (PET) polypeptide probe and the preparation method thereof, a glycine is added to the TMTP1, and a G-TMTP1 polypeptide is designed, so that the polypeptide does not influence the biological activity after being radioactively marked; furthermore, 18F is taken as a radionuclide, and the G-TMTP1 polypeptide is marked by utilizing a [<18>F] AlF-NOTA method, so that the obtained [<18>F] AlF-marked PET polypeptide probe has excellent pharmacokinetics properties, the background cleaning rate is high, the liver uptake rate is low, in-vivo stability is good, the uptake rate of tumor site is high, highly metastatic tumor can be diagnosed specifically, and the polypeptide probe can be applied to diagnosis or therapeutic evaluation of highly metastatic malignant tumor.

The invention belongs to the technical field of gene engineering and discloses a prime-probe combination for detecting fusion genes of leukemia, a kit containing the prime-probe combination and a multiplex fluorescent RT-PCR method for detecting the fusion genes of the leukemia by virtue of the prime-probe combination or the kit. Based on a multiplex fluorescent RT-PCR technique, the method is simple, rapid and high in sensitivity. Besides, by virtue of the reasonable prime-probe combination, the mutual action between the two primers, the prime and the probe as well as two probes are effectively avoided, and the detection error is reduced. By virtue of the method, 45 fusion genes of the leukemia can be comprehensively and qualitatively detected, the detection time is effectively shortened, and very important detection measures are provided for the evaluation of clinical diagnosis and treatment and the prognosis of the leukemia.

The invention discloses a serum miRNA combination-based pulmonary tuberculosis therapeutic effect evaluation kit and applications thereof. The kit comprises an RNA extraction buffering solution, a Poly (A)-containing reaction solution, a reverse transcription reaction solution, a serum miRNA upstream primer combination, an internal reference upstream primer, a universal downstream primer and a fluorescent quantitation RT-PCR reaction solution, wherein the serum miRNA upstream primer combination comprises four differentially expressed serum miRNA: hsa-miR-21-5p, hsa-miR-92a-3p, hsa-miR-125a-5p and hsa-miR-148b-3p, the sequences of which are respectively SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4; the internal reference is hsa-miR-16, the sequence of which is SEQ ID NO:5. The detection sensitivity of the kit on treatment of pulmonary tuberculosis is 65.38%, and the specificity is 80.77%, so that the specificity is strong and the sensitivity is high, and the kit has higher accuracy, and is simple and convenient to operate, high in efficiency, small in specimen state limit, and superior to the sputum culture currently clinically adopted, thus providing a new evaluation method for the evaluation on the therapeutic efficacy of pulmonary tuberculosis.

The invention provides a characteristic protein fragment composition for detecting thalassemia and a mass spectrometry model for evaluating therapeutic effect of thalassemia medicine or evaluating effect of a treatment method, wherein the sequence of the characteristic protein fragment composition is shown in SEQ ID No.1-3, respectively. The characteristic protein fragment composition or mass spectrometry model provided by the invention can be used for the diagnosis and screening of thalassemia, as well as the evaluation of the treatment method and drug efficacy of thalassemia. The method is simple and easy to operate, and high in accuracy, and provides new methods and ideas for the evaluation of diagnosis and screening, treatment methods and drug efficacy of thalassemia.

The invention discloses a multispectral tongue picture collecting device which comprises a box body, wherein a tongue body detection opening is formed in one side of the box body; a digital camera is arranged on the other side of the box body through penetrating through the box body wall; a light source is arranged on the inner surface of the box body; an optical lens is arranged inside the box body; the tongue body detection opening and the digital camera are positioned in the image conjugate positions on the two sides of the optical lens respectively; and a light splitting device is arranged between the optical lens and the digital camera. The multispectral tongue picture collecting device provided by the invention acquires the multispectral information of the detected tongue body at last through acquiring multispectral images of the tongue body; through combination of three dimensional information of a first dimensional light spectrum and a second dimensional image of the tongue body, physiological and pathological information brought by the tongue body can be reflected, so that more objective information can be provided for doctors of Chinese medicine for tongue diagnosis, and the accuracy in clinical diagnosis of the doctors of Chinese medicine can be improved; and meanwhile through the comparison of the tongue body three dimensional information of a patient in different stages, objective references can be provided for evaluation of clinical curative effect of doctors of Chinese medicine.

The invention relates to a method for evaluating and optimizing blood vessel photodynamic therapeutic effects of different light dosages on the same experimental animal, in particular to therapeutic effects of a photodynamic method is used for treating vascular disease, such as nevus flammeus and choroidal vessels, and the method can be used for evaluating and optimizing illumination parameters of a pulse dye laser and other photo-thermal therapy for treating the vascular disease. According to the method, structured light irradiation with preset dosage is performed on the same experimental animal, and the method comprises the main steps of sample dissecting and dyeing, sample slicing and three-dimensional reconstructing, and experimental data analyzing and evaluating, thereby obtaining the therapeutic evaluations of different light dosages on the same experimental animal. Through the method, clinical experiment animals can be greatly reduced, the evaluations of therapeutic effects of blood vessels in different depths and diameters can be provided, and the determination of the optimal illumination dosage is accelerated.

The invention relates to the technical field of bioengineering and discloses a VEGF (vascular endothelial growth factor) monoclonal antibody and a fracture healing evaluation antibody chip with the same. The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO.2. Homogeneity and biological activity unicity of the monoclonal antibody enables antigen antibody reaction results to be convenient for quality control and beneficial to standardization and normalization. The chip with the monoclonal antibody can be directly applied to clinical therapeutic evaluation on fracture healing, solves the technical problems of time and labor consumption, poor result repeatability and the like of the prior art, has extremely high application value in the field of clinical treatment and has wide application prospect.

A standardized therapy management system used for hematological malignancy patients comprises a data base, a recording module, an evaluation module and a statistics module. The standardized therapy management system used for hematological malignancy patients comprehensively records disease information of the patients; provides standardized therapy, evaluation procedure and examination and testing methods; and manages therapeutic evaluation time and reexamination time nodes of the patients in standardized mode. Doctors can improve the capability of clinician standardized therapy management through the statistics module, work omissions caused by inadequate experience and negligence can be reduced, and state, curative effect and prognoses of the hematological malignancy patients can be evaluated through the evaluation module.

The invention provides a diagnostic kit for detecting Paragonimiasis, which contains a rabbit polyclonal antibody against the soluble antigen of Paragonia wescheri adult worm, an enzyme-labeled rabbit polyclonal antibody against the soluble antigen of Paragonimus westermani adult worm, Nitrocellulose membrane, bovine serum albumin, PBST washing solution, substrate chromogenic solution, positive control sample, negative control sample and polyethylene reaction plate. The invention also provides a preparation method of a diagnostic kit for detecting paragonimiasis. The invention adopts the double-antibody sandwich method Dot-ELISA to detect the circulating antigen of Paragonimus westermani, has high sensitivity and strong specificity, and can realize rapid diagnosis and curative effect assessment of Paragonimiasis.

The invention provides a kit for detecting circulating antigens of Agkistrodon acutinae using specific polyantibody, comprising rabbit anti-Aag-IgG, enzyme-labeled antibody (HRP-Aag-IgG), nitrocellulose film, 1 % bovine serum albumin in PBST solution, PBST washing solution, substrate chromogenic solution, positive and negative control sample composition and polyethylene reaction plate. The invention also provides a preparation method of a kit for detecting circulating antigens of Agkistrodon acutina by using specific polyantibody. The invention adopts the polyclonal antibody to measure the circulating antigen, which is beneficial to making early diagnosis and helping to judge the prognosis. When the parasites in the body die, the circulating antigens disappear quickly, which can be used for efficacy assessment. The kit of the invention has high sensitivity and strong specificity, and can realize rapid diagnosis, drug screening and curative effect assessment of Agkistrodon acutinae ligamentiworm disease.

The invention relates to an online analysis system, and the system comprises a curative effect evaluation module. The curative effect evaluation module comprises a data obtaining unit which is used for extracting data corresponding to a doctor recommended dose, an actual medicine taking dose and an INR from a database; a curve graph drawing unit which is used for drawing a curve graph by taking the dosage recommended by the doctor, the actual medicine taking dosage and the INR as vertical coordinates and taking time as horizontal coordinates, and obtaining a patient compliance index through the difference of the two generated curves; and a data annotation unit which is used for calculating the time percentage of the part not exceeding the target INR in the INR curve graph. According to theonline analysis system, the INR curve graph is obtained, the part, not exceeding the target INR, in the INR curve graph is marked, the marked curve graph and the calculated time percentage are displayed on a doctor terminal and a patient terminal, and the intelligent level can be improved by adopting the online analysis system.

The invention discloses synthesis and an application of a FePt/GO nanocomposite based diagnosis and treatment reagent. A nano FePt/GO composite is taken as the core, and fluorescein isothiocyanate (FITC) and folic acid are connected by polyethylene glycol (PEG). Based on the design, the invention constructs a diagnosis and treatment nano probe which integrates multi-target (molecular level and external magnetic field), bimodal imaging diagnosis (MRI and fluorescence) and dual treatment (chemotherapy and thermal therapy) to treat the selected tumor, thereby achieving the central goal of early target diagnosis and synchronous in situ treatment of tumors. According to the nano probe, the main synthesis manner comprises low temperature microwave radiation-liquid phase synthesis, and graphene is taken as a carrier to control the synthesis of the FePt/GO nanocomposite. The core relates to controlled synthesis of FePt/GO nanocomposite, physicochemical property research, surface finish, target bimodal imaging in cellular level (invitro) and synchronous in situ treatment bimodule imaging location, and visualization treatment and curative effect evaluation.

The invention discloses a reagent kit for quantitatively testing mRNA (messenger ribonucleic acid) level of FIP1L1-PDGFRA (feline infectious peritonitis 1 like 1-platelet-derived growth factor receptor alpha) fusion genes. The test reagent contains upstream primers I, downstream primers I and TaqMan probes I which are used for real-time quantitative PCR (polymerase chain reaction) testing for mRNA of the FIP1L1-PDGFRA fusion genes. The upstream primers I include at least one of single-chain DNA (deoxyribose nucleic acid) shown as sequences 1, 2, 3, 4 and 5 in a sequence table, the downstream primers I include at least one of two single-chain DNA as shown in sequence 9 and 10 in the sequence table, and the TaqMan probes I include at least one of two single-chain DNA as shown in sequences 9 and 10 in the sequence table. The reagent kit has the advantages of speediness, simplicity, convenience and the like in testing, common types of FIP1L1-PDGFRA fusion genes can be covered in one experiment, and the mRNA level of the FIP1L1-PDGFRA fusion genes can be tested. The reagent kit can be used for FIP1L1-PDGFRA fusion gene screening and therapeutic evaluation for eosinophilia patients, and further can be used for monitoring minimal residual diseases.

The invention relates to a pair of coelomic mucosa calibrating biopsy forceps, which comprise a handle. A sliding groove is arranged in the lateral direction of the handle. A soft tube is connected to one end of the handle. The other end of the soft tube is connected with the biopsy forceps through a biopsy joint. An injection needle is arranged in the middle of the biopsy forceps. The injection needle passes through the biopsy joint and the soft pipe and is connected with a needle pushing rod. An injection interface is communicated with the needle pushing rod. A handlebar is arranged at the other end of the handle. A steel wire on the handlebar is connected with the biopsy joint. The coelomic mucosa calibrating biopsy forceps disclosed by the invention have the benefits that: the coelomic mucosa calibrating biopsy forceps are used for pre-cancerous pathological examination of various coelomic mucosa and long-term follow up and preventing from not calibrating after minute lesion biopsy, therefore, the effective treatment cannot be carried out in the operation because of not judging focus; and the correct therapeutic evaluation can be given on prognosis of pre-cancerous lesion pharmacotherapy.

The invention relates to the field of near-infrared imaging, in particular to a near-infrared fluorescent small molecular probe and preparation thereof and application of the near-infrared fluorescentsmall molecular probe in the field of myelin sheath imaging. The structural formula of the small molecular probe is shown in the following figure, and fluorescence performance tests show that the emission wavelength of the small molecular probe is greater than 650nm, and the small molecular probe enters a near-infrared region. Meanwhile, the small molecular probe can be effectively combined witha myelin sheath part, the imaging effect of the myelin sheath part is remarkably enhanced, the small molecular probe can be applied to myelin sheath imaging under the near-infrared condition, and a brand-new method can be provided for diagnosis and curative effect evaluation of central nervous system diseases such as multiple sclerosis.